A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 96fbf6b28b22ebed-LAX IP: 47.97.18.252 UTC time: 2025-08-15T22:00:14+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4